Biotage AB appointment of new CEO

15-Aug-2024
Computer-generated image

Symbolic image

BiotageAB announced the appointment of Frederic Vanderhaegen as chief executive officer, effective September 16th 2024. Mr. Vanderhaegen succeeds Torben Jørgensen, who stepped in as interim CEO in January 2024 and he will now continue as a board member.

Frederic Vanderhaegen is a prominent life science leader with 30+ years’ experience leading complex organisations with portfolios including laboratory products, diagnostics, and medical devices. He is ideally positioned to lead the company through its next ambitious phase of growth.

Frederic joins Biotage from Avantor where he was General Manager and Executive Vice President for Europe. He also led the global portfolio for the life science business, sourcing and commercial excellence teams. Prior to Avantor, he worked for Ortho Clinical Diagnostics, Danaher, Tecan and Millipore in various senior leadership positions.

Frederic holds a Biochemical Engineering degree from Haute Ecole Lucia Debroeckere, a Chemical and Agricultural Engineering degree from Universite Libre de Bruxelles and an MBA from the Open University.

Other news from the department business & finance

Most read news

More news from our other portals

Last viewed contents

Dr. Christine Munz becomes CEO at Eppendorf - Dr. Wilhelm Plüster completes term in office as planned

Dr. Christine Munz becomes CEO at Eppendorf - Dr. Wilhelm Plüster completes term in office as planned

Beckman Coulter Life Sciences Names Joe Fox President

Beckman Coulter Life Sciences Names Joe Fox President

Nobel Prize in Medicine for immune system guardians - Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases

Nobel Prize in Medicine for immune system guardians - Two Americans and one Japanese scientist honored for revolutionary discoveries on the balance of the immune system in autoimmune diseases

GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026

GEA Supervisory Board takes early decision to extend contract of CEO Stefan Klebert - Company resolves to restructure the Executive Board and streamline the organizational structure as of January 1, 2026

Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership

Mosaic Therapeutics appoints Thomas Fuchs as CEO - Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadership

WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership

WIKA strengthens management team with Axel Schwerdtfeger - Process Solutions company division under new leadership

Otto Warburg Medal 2026 awarded to Maya Schuldiner

Otto Warburg Medal 2026 awarded to Maya Schuldiner

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

Research on rewiring neural circuit in fruit flies wins 2025 Eppendorf & Science Prize

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”

Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”

Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research

Waters Corporation and Princeton University Announce Multi-Year Research Collaboration - Agreement to take on real-world challenges in biologics and materials research

New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments

New biotech venture PHIOGEN to tackle the global threat of antimicrobial resistance - By optimizing nature’s defenders, the team has produced unprecedented phage treatments

CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need

CureVac and MD Anderson enter strategic collaboration to develop novel cancer vaccines - Collaboration aims to develop novel, off-the-shelf, mRNA-based cancer vaccines in selected hematological and solid cancers with high unmet medical need